Europe Phase IV Clinical Trials Market Size, Share & COVID-19 Impact Analysis, By Deployment (In-house and Outsource), By Disease Indication (Oncology, Neurology, Cardiology, Infectious Disease, Metabolic Disorder, Renal/Nephrology, and Others), By Type (Interventional and Non-interventional), and Regional Forecast, 2023-2030

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI108062

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 5.1% from 2023-2030
Unit	Value (USD billion)
Segmentation	Deployment; Disease Indication; Type; and Country/Sub-region
By Deployment	In-house Outsource
By Disease Indication	Oncology Neurology Cardiology Infectious Disease Metabolic Disorder Renal/Nephrology Others
By Type	Interventional Non-interventional
By Country/Sub-region	Europe (by Deployment, by Disease Indication, by Type, and by Country/Sub-region) Germany U.K. France Italy Spain Rest of Europe